SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed Jul 15, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 15, 2026 at 07:00 ET

Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting, which reduces regulatory uncertainty. This is a procedural milestone for a mid-stage pipeline asset, not a revenue-generating event, and the stock's historical reaction to neutral filings has been negative on average.

  • FDA accepted NDA filing for AXS-12 (reboxetine) to treat cataplexy in narcolepsy
  • PDUFA target action date set for May 1, 2027
  • FDA indicated no advisory committee meeting is currently planned
  • AXS-12 has Orphan Drug Designation for narcolepsy

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access